FIELD: biotechnology.
SUBSTANCE: claimed invention relates to biotechnology, more specifically, to the drug antibodies secukinumab, where cysteine is selectively restored at position 97 of the light chain secukinumab, in which the level of intact secukinumab in the drug is at least approximately 90% as measured by capillary electrophoresis with sodium dodecyl sulfate (CE-SDS), and where the level of the secukinumab activity in the said drug is at least approximately 90% as measured by cation-exchange chromatography (CEX).
EFFECT: proposed is selective reduction of cysteine residues in antibodies against IL-17.
13 cl, 17 dwg, 53 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN ANTIBODIES AGAINST IL-17 | 2015 |
|
RU2719563C2 |
| LIQUID COMPOSITION CONTAINING ANTIBODY TO HUMAN INTERLEUKIN-4 RECEPTOR ALPHA | 2020 |
|
RU2814172C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY | 2018 |
|
RU2813990C2 |
| STRUCTURE OF POLYPEPTIC ANTIBODIES | 2015 |
|
RU2725812C2 |
| POLY-SPECIFIC ANTIBODY STRUCTURES | 2015 |
|
RU2784673C2 |
| MULTISPECIFIC ANTIBODY WITH BINDING SPECIFICITY OF HUMAN IL-13 AND IL-17 | 2020 |
|
RU2827946C1 |
| PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF | 2018 |
|
RU2749342C1 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
